ICAR GUIDELINES Bundle (free trial)

Rhinology and Allergy Rhinosinusitis

ICAR IFAR GUIDELINES brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1512430

Contents of this Issue

Navigation

Page 18 of 27

19 Cost Benefit-Harm Assessment Policy Level Low additional cost to achieve target MAP Preponderance of benefit over harm Option: Controlled hypotension (MAP between 60 and 70 mmHg ) is safe and improves the surgical field Ignorance of individual specific symptoms or loss of productivity at work if criteria for surgery not met Likely benefit over harm with acknowledgement that certain patients with low SNOT-22 may still benefit from surgery Option: Patient selection for surgical intervention should take into consideration baseline patient-reported symptom burden Balloon-dilation technolog y is associated with increased equipment costs per case In short term follow-up, conservative approaches do not appear to increase harm from recurrence in patients with limited sinus disease Option: Less extensive sinus interventions are likely reasonable options in patients with minimal OMC or maxillary sinus disease Costs related to longer operating time and the need for specialized equipment Preponderance of benefit over harm in selected cases Option: Use in patients undergoing ESS, especially in the setting of anatomic complexity or the need for more advanced procedures

Articles in this issue

view archives of ICAR GUIDELINES Bundle (free trial) - Rhinology and Allergy Rhinosinusitis